meta
|
evidence
COVID-19
Living systematic review and meta-analysis
adjuvant therapies
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
anti GM-CSF
mavrilimumab
Namilumab
otilimab
clarithromycine
colchicine
Colchicine plus rosuvastatin
mepolizumab
naproxen, ibuprofen
non-steroidal anti-inflammatory drugs
Celecoxib
Ibuprofen
Indomethacin
selinexor
sodium aescinate
stem cells
tradipitant
vilobelimab (IFX-1)
Apilimod
corticosteroids
ciclesonide
dexamethasone
Dexamethasone 12mg
dexamethasone 6mg
Hydrocortisone
low-dose corticosteroids
methylprednisolone
Immunostimulants drugs
anti-PD-1 antibody
CD24Fc
convalescent plasma treatment
Deferred Convalescent plasma
Early convalescent plasma.
immunoglobulin therapy
inactivated mycobacterium vaccine
interferon
IFN beta-1a
high-dose IFN beta-1a
IFN beta-1b
IFN gamma
inhaled interferon
IFN alpha
pegylated interferon-α2b
recombinant super-compound interferon rSIFN-co
SNG001 inhaled interferon beta
interferon / TFF2
peginterferon
PNB001
Interleukin-2
levamisole
neutralizing antibody
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences)
bamlanivimab monotherapy
bamlanivimab/etesevimab
Bebtelovimab (LY-CoV1404)
bevacizumab
casirivimab/imdevimab (Ronapreve)
cilgavimab and tixagevimab (Evusheld)
equine polyclonal antibodies INM005
regdanvimab (Regkirona- CT-P59-Celltrion)
sotrovimab (Xevudy; VIR-7831)
XAV-19
rhG-CSF
Immunosuppressants drugs
abatacept
adalimumab
anakinra
anti-interleukin-6
clazakizumab
Levilimab
sarilumab
sarilumab azithromycin hydroxychloroquine
sarilumab high dose (400mg)
sarilumab low dose (200mg)
siltuximab
tocilizumab
canakinumab
cenicriviroc
complement inhibitors
conestat alfa
ravulizumab
CRAC-channel inhibitors (auxora)
eculizumab
emapalumab
fostamatinib
infliximab
itolizumab
ixekizumab
jakotinib
janus kinase (JAK) inhibitor
baricitinib
baricitinib plus remdesivir
ruxolitinib
TD-0903
TD-0903 10mg
TD-0903 1mg
TD-0903 3mg
tofacitinib
lenzilumab
pamrevlumab
tacrolimus
tetrandrine
thalidomide
inhaled corticosteroids
budesonide
Kinase inhibitors
acalabrutinib
imatinib
leflunomide
meplazumab
pirfenidone
Polyinosinic-Polycytidylic Acid
sargramostim
statins
Atorvastatin
thymosin
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
Vitamins
potential COVID-19 treatments
adjuvant therapies
paracetamol
anti-inflammatoty and immuno-therapy
corticosteroids
dexamethasone
dexamethasone 6mg
Immunostimulants drugs
convalescent plasma treatment
Deferred Convalescent plasma
interferon
IFN beta-1a
inhaled interferon
IFN alpha
neutralizing antibody
casirivimab/imdevimab (Ronapreve)
Immunosuppressants drugs
anti-interleukin-6
tocilizumab
antiviral and associated therapy
favipiravir
hydroxychloroquine plus macrolides
azithromycin plus hydroxychloroquine
lopinavir/ritonavir
control
placebo
standard of care
Vitamins
vitamin C
All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
patient subgroup...
age >= 55 yr
age >= 60 yr
age >= 65 yr
autoimmune disease
corticosteroids: no
corticosteroids: yes
critical disease
invasive ventilation
no oxygen needed
non invasive oxygen
omicron variant BA.1 (B.1.1.529)
severe disease
solid organ transplant recipients
subjects at risk
Studies
Mapping
Meta-analysis
Excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded